Literature DB >> 10852793

Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects.

J D Brannan1, S D Anderson, R Freed, J D Leuppi, H Koskela, H K Chan.   

Abstract

Nedocromil sodium inhibits the response to exercise-induced asthma (EIA). Mannitol given as a powder by inhalation is an osmotic stimulus that identifies EIA. We studied the acute effect of nedocromil on airway responsiveness to mannitol in 24 asthmatic subjects. After a control day, nedocromil (8 mg) or its placebo was administered randomized, double blind, 10 min before a challenge with progressively increasing doses of mannitol. Nedocromil inhibited the response to mannitol and there was a significant increase in the dose of mannitol required to cause a 15% reduction in FEV(1) (PD(15)) after nedocromil 409 (316,503) mg compared with placebo 156 (106,229) mg (p < 0.001). In the presence of nedocromil 12 subjects no longer recorded a 15% decrease in FEV(1) in response to mannitol. The remaining 12 required a significantly greater dose of mannitol to achieve a 15% decrease in FEV(1) after nedocromil. Following nedocromil, a plateau in responsiveness to mannitol was observed in 14 subjects. Nedocromil significantly inhibits the responsiveness to inhaled mannitol in asthmatic subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852793     DOI: 10.1164/ajrccm.161.6.9908096

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

Review 1.  Asthma outcomes: pulmonary physiology.

Authors:  Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

2.  The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma.

Authors:  John D Brannan; Johan Bood; Ahmad Alkhabaz; David Balgoma; Joceline Otis; Ingrid Delin; Barbro Dahlén; Craig E Wheelock; Parameswaran Nair; Sven-Erik Dahlén; Paul M O'Byrne
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

Review 3.  Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Clin Rev Allergy Immunol       Date:  2003-02       Impact factor: 8.667

4.  Pulmonary function assessment in the early phase of patients with smoke inhalation injury from fire.

Authors:  Cheol-Hong Kim; Heungjeong Woo; In Gyu Hyun; Won Jun Song; Changhwan Kim; Jeong-Hee Choi; Dong-Gyu Kim; Myung Goo Lee; Ki-Suck Jung
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

5.  Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.

Authors:  John D Brannan; M Diane Lougheed
Journal:  Front Physiol       Date:  2012-12-10       Impact factor: 4.566

6.  Airway inflammation and mannitol challenge test in COPD.

Authors:  Selma B de Nijs; Niki Fens; Rene Lutter; Erica Dijkers; Frans H Krouwels; Barbara S Smids-Dierdorp; Reindert P van Steenwijk; Peter J Sterk
Journal:  Respir Res       Date:  2011-01-18

7.  Cough response to isocapnic hyperpnoea of dry air and hypertonic saline are interrelated.

Authors:  Minna Purokivi; Heikki Koskela; John D Brannan; Kirsi Kontra
Journal:  Cough       Date:  2011-10-14

8.  The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline.

Authors:  John D Brannan; Sandra D Anderson; Clare P Perry; Ruth Freed-Martens; Anna R Lassig; Brett Charlton
Journal:  Respir Res       Date:  2005-12-09

Review 9.  The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations.

Authors:  Asger Sverrild; Joanna Leadbetter; Celeste Porsbjerg
Journal:  Respir Res       Date:  2021-11-07

10.  Use of mannitol inhalation challenge in assessment of cough.

Authors:  Sheldon Spector
Journal:  Lung       Date:  2009-09-16       Impact factor: 2.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.